Litigation Details for Shire Development LLC v. Apotex, Inc. (D. Del. 2015)

« Back to Dashboard

Shire Development LLC v. Apotex, Inc. (D. Del. 2015)

Docket		Date Filed	2015-11-12
Court	District Court, D. Delaware	Date Terminated	2017-02-08
Cause	35:0145	Assigned To	Leonard Philip Stark
Jury Demand	Defendant	Referred To	Christopher J. Burke
Patents	7,381,428; 7,465,465
Link to Docket	External link to docket

Details for Shire Development LLC v. Apotex, Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-11-12				External link to document
2015-11-11	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,968,976; 7,381,428; 7,465,465;. …2015 8 February 2017 1:15-cv-01045 830 Patent Defendant District Court, D. Delaware	External link to document
2015-11-11	50		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,968,976; 7,381,428; 7,465,465. (…2015 8 February 2017 1:15-cv-01045 830 Patent Defendant District Court, D. Delaware	External link to document

Shire Development LLC v. Apotex, Inc. | 1:15-cv-01045 Litigation Summary

Last updated: August 3, 2026

Shire Development LLC v. Apotex, Inc., No. 1:15-cv-01045, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Apotex’s abbreviated new drug application for generic Lialda, Shire’s delayed-release mesalamine product. The dispute involved patents covering mesalamine dosage forms and pH-dependent delivery technology. The case ended without a public merits judgment, and the docket reflects termination through a settlement-related dismissal. The settlement terms and any authorized Apotex launch date were not publicly disclosed in the case docket. [1]

What drug was at issue in Shire v. Apotex?

The case concerned Lialda, a prescription delayed-release tablet containing mesalamine, also known as 5-aminosalicylic acid or 5-ASA.

Item	Information
Brand	Lialda
Active ingredient	Mesalamine
Dosage form	Delayed-release tablet
Strength	1.2 grams
FDA indication	Induction and maintenance of remission in adults with ulcerative colitis
Reference sponsor	Shire Development LLC and affiliated Shire entities
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Generic applicant	Apotex, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-01045
Litigation type	Hatch-Waxman patent infringement action

Lialda uses a delayed-release coating designed to resist release in the stomach and release mesalamine at a higher-pH region of the gastrointestinal tract. The formulation was commercially important because the tablet permitted once-daily dosing for many patients, compared with older mesalamine products that often required more frequent administration. [2]

What patents protected Lialda in the Apotex litigation?

The complaint was based on patent rights listed for Lialda and challenged by Apotex’s ANDA. The central patent estate included patents relating to mesalamine compositions, multilayer tablets, enteric coatings, and controlled release.

Publicly associated Lialda patents included the following:

Patent	General subject matter	Relevance to Lialda
U.S. Patent No. 6,773,720	Controlled-release mesalamine composition	Foundational formulation and delivery technology
U.S. Patent No. 8,337,886	Mesalamine dosage forms and release characteristics	Later formulation protection
U.S. Patent No. 8,496,965	Mesalamine compositions and manufacturing or formulation features	Follow-on formulation protection
U.S. Patent No. 8,945,604	Mesalamine compositions and treatment-related claims	Later Orange Book-listed protection
U.S. Patent No. 9,585,838	Additional Lialda-related formulation or use claims	Later-stage patent coverage

The patents asserted in a particular ANDA action must be distinguished from the broader Orange Book estate. A brand company may list several patents for a product, while asserting only a subset against a specific generic applicant. The operative complaint, amended pleadings, and Paragraph IV notice determine the claims actually placed in dispute. [1, 3]

When does Lialda lose patent and regulatory exclusivity?

Lialda’s exclusivity profile has two separate components: FDA regulatory exclusivity and patent exclusivity.

FDA regulatory exclusivity

Lialda was approved before the modern five-year new chemical entity exclusivity period became commercially relevant to this product. Its principal barriers to generic entry were therefore patent rights, not a remaining period of FDA data exclusivity.

For a small-molecule product such as Lialda, an ANDA applicant may file a Paragraph IV certification asserting that listed patents are invalid, unenforceable, or not infringed. The filing can trigger a patent infringement action and a statutory 30-month stay of FDA approval under the Hatch-Waxman Act. [4]

Patent expiration

The earliest foundational Lialda patent, U.S. Patent No. 6,773,720, had an expiration date in 2020, subject to patent-term adjustment and the specific Orange Book record. Later patents extended protection for selected formulation and method-of-use features beyond the foundational patent.

The commercial effect was that expiration of the '720 patent did not necessarily eliminate every patent barrier. A generic applicant still had to address later-listed patents or obtain a settlement license covering them.

What Paragraph IV challenge did Apotex make?

Apotex filed an ANDA seeking approval to market a generic version of Lialda delayed-release tablets. Its Paragraph IV certification challenged one or more listed Shire patents. Shire then filed the Delaware action within the 45-day statutory period, creating the statutory approval stay applicable to the challenged patents. [1, 4]

The principal legal issues in this type of case were:

1. Whether Apotex’s proposed mesalamine tablet infringed the asserted composition and formulation claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether the asserted claims were unenforceable because of inequitable conduct or other defenses.
4. Whether the ANDA product would practice claimed release, coating, or dosage-form limitations.
5. Whether later-listed patents created independent barriers to approval or commercial launch.

The case did not produce a publicly reported trial judgment establishing that Apotex’s product infringed or that the asserted patents were invalid. The settlement disposition therefore carries greater commercial significance than any judicial merits holding.

What was the litigation timeline?

Date or period	Event
2015	Shire filed the patent infringement action after Apotex’s ANDA-related Paragraph IV challenge
2015-2016	Pleadings, ANDA-related discovery, and development of infringement and invalidity positions
2016-2017	Claim-construction and case-management activity occurred in the Delaware action
Before merits judgment	The parties resolved the dispute through a settlement
Case termination	The action was dismissed pursuant to the parties’ settlement-related filing
Post-settlement period	Apotex’s commercial launch rights were governed by confidential settlement terms and applicable FDA approval conditions

The public docket does not establish a finding of infringement, invalidity, inequitable conduct, or noninfringement. It also does not publicly disclose the settlement’s launch date, royalty structure, or restrictions on Apotex’s commercialization. [1]

What was the settlement outcome?

The case ended through settlement rather than a publicly adjudicated decision. In a Hatch-Waxman case, a settlement commonly grants the generic applicant a license to enter before the expiration of some or all asserted patents, subject to conditions such as:

• A fixed launch date.
• Earlier entry if another generic launches.
• A royalty on generic sales.
• Restrictions tied to specific patents or dosage strengths.
• Non-compete or supply arrangements.
• A provision addressing FDA approval timing.

The docket does not provide a public basis to assign any of those provisions to the Shire-Apotex agreement. The commercially relevant conclusion is that the litigation did not result in a public injunction after trial and did not establish a judicially enforceable prohibition against Apotex’s eventual entry beyond the settlement terms.

A settlement also does not establish that the patents were weak. Shire avoided the cost and risk of trial, while Apotex obtained a negotiated path to market. The absence of a merits ruling limits the value of the case as precedent for claim construction, obviousness, or infringement analysis.

What was the Orange Book status of Lialda?

The Orange Book listed patents for Lialda that covered more than the active ingredient itself. The relevant protection focused on the drug product and its delivery system, including delayed release and pH-dependent dissolution characteristics.

For generic applicants, the Orange Book analysis required a patent-by-patent review of:

Issue	Business effect
Listed formulation patent	Could delay approval or require a Paragraph IV challenge
Method-of-use patent	Could require a Section viii carve-out or acceptance of a narrower label
Patent expiration	Determined whether an ANDA could launch without a license
Patent-term adjustment	Could extend the practical end date beyond the nominal 20-year term
30-month stay	Delayed FDA approval after timely patent litigation
Settlement license	Could permit earlier entry than an unlicensed launch

The Orange Book must be evaluated by product strength and listing status. A patent listed against Lialda 1.2-gram delayed-release tablets may not automatically apply to every mesalamine dosage form or competing product. [3]

How strong was Shire’s Lialda patent estate?

Shire’s Lialda estate had moderate-to-strong commercial characteristics because it combined foundational formulation claims with later patents directed to specific dosage-form and release attributes.

Strengths

The estate had several practical advantages:

• It protected a formulated product rather than only a chemical compound.
• The product’s delayed-release behavior could be difficult to design around while retaining the same clinical and dosing profile.
• Multiple patents created layered barriers after expiration of the earliest patent.
• An ANDA applicant had to address both infringement and invalidity across different claim sets.
• FDA approval could be delayed by the statutory litigation stay.

Weaknesses

The estate also had conventional pharmaceutical patent risks:

• Formulation claims are vulnerable to obviousness attacks based on known enteric coatings, pH-dependent polymers, excipients, and release profiles.
• Continuation and follow-on patents may face written-description, enablement, and double-patenting challenges.
• A generic manufacturer may redesign coating thickness, polymer composition, tablet architecture, or dissolution performance.
• Patent expiration dates differed across the estate, creating a declining rather than absolute barrier.
• Settlement prevented a public court ruling that could have clarified claim scope.

The strongest commercial protection likely came from claims that mapped directly onto the finished Lialda tablet and its release profile. Method-of-use claims were more vulnerable to label carve-outs if the generic could omit protected indications without preventing approval for an unpatented use.

Did biosimilar risk apply to Lialda?

No. Lialda is a small-molecule mesalamine product, not a biologic. Biosimilar provisions under the Biologics Price Competition and Innovation Act did not apply.

The relevant competitive pathway was an ANDA for a generic equivalent, with therapeutic-equivalence and pharmaceutical-equivalence requirements governed by the Federal Food, Drug, and Cosmetic Act. The case therefore involved generic substitution risk, not biosimilar interchangeability or biologics patent dance procedures. [4, 5]

Which companies challenged Lialda patents?

Lialda faced broader generic competition from multiple ANDA applicants, including companies involved in separate patent cases or regulatory challenges. The competitive field included major generic manufacturers such as Teva, Mylan, Zydus, and Apotex, although each applicant’s litigation posture, product design, settlement date, and launch rights were distinct.

A settlement with Apotex did not resolve the patent position of other applicants. Each ANDA applicant could pursue a separate Paragraph IV challenge, negotiate a separate license, or wait for patent expiration.

What generic launch risks did Shire face?

Shire faced several potential launch scenarios:

Scenario	Result
Apotex wins on noninfringement	Apotex could obtain approval and launch subject to remaining patents
Apotex invalidates asserted patents	Earlier unrestricted entry could follow
Apotex loses after trial	Approval could remain blocked until patent expiration or settlement
Settlement with licensed entry	Apotex could launch on the negotiated date
Another generic launches first	Later settlements could become commercially less valuable
At-risk launch	Generic could launch before final resolution, exposing itself to damages and injunction risk

The principal risk was price erosion in Lialda’s U.S. franchise. Delayed-release mesalamine products compete on tablet strength, dosing frequency, insurance formulary placement, and substitution status. Once an FDA-approved generic becomes available, branded net sales can decline even if the brand retains patients through rebates, contracts, or physician preference.

Did the case involve licensing or co-commercialization?

The public case record establishes settlement, but it does not disclose a public license agreement, royalty rate, co-commercialization arrangement, or supply transaction between Shire and Apotex. Any license granted through settlement should be treated as confidential unless disclosed in a regulatory filing, antitrust review record, or later litigation.

No public record from this docket establishes that Apotex received an unrestricted license to launch immediately upon FDA approval.

What is the current litigation status?

The case is closed. It did not culminate in a publicly reported final judgment after trial. The litigation’s current value is primarily transactional and historical:

• It documents Apotex’s Paragraph IV challenge to Lialda-related patents.
• It shows that Shire resolved the dispute through settlement.
• It does not provide controlling precedent on the validity or infringement of the asserted patents.
• It does not, by itself, establish Apotex’s launch date or market share.
• It should be analyzed together with the Orange Book, FDA approval records, later generic litigation, and any public settlement disclosures.

Key Takeaways

• Shire Development LLC v. Apotex, No. 1:15-cv-01045, was a Hatch-Waxman case involving generic Lialda mesalamine delayed-release tablets.
• Apotex challenged Shire’s listed Lialda patents through the Paragraph IV process.
• The case ended by settlement and dismissal, without a public merits judgment.
• The relevant patent estate included foundational and follow-on formulation patents, including U.S. Patent Nos. 6,773,720 and 8,337,886.
• Lialda’s commercial protection came primarily from formulation and delivery patents, not biosimilar exclusivity.
• The settlement terms, royalty provisions, and authorized Apotex launch date were not publicly disclosed in the docket.
• The case does not establish that the Lialda patents were valid, invalid, infringed, or not infringed.
• Generic entry risk remained dependent on later patents, separate ANDA litigation, FDA approval, and settlement licenses with other applicants.

FAQs

Was Shire v. Apotex a patent infringement case or an FDA case?

It was a patent infringement case filed under the Hatch-Waxman framework after Apotex submitted an ANDA with Paragraph IV certifications. FDA approval was relevant to the statutory stay and generic entry, but the court action concerned patent infringement and validity.

Did Apotex invalidate the Lialda patents?

No public merits judgment in this case established invalidity. The action was resolved by settlement before a reported trial decision.

What was the earliest important Lialda patent expiration date?

U.S. Patent No. 6,773,720, a foundational Lialda-related patent, expired in 2020, subject to the applicable patent-term adjustment and Orange Book record.

Could Apotex launch generic Lialda immediately after settling?

Not necessarily. A settlement may authorize launch only on a specified date or after satisfaction of FDA and patent-related conditions. The Apotex settlement terms were not publicly disclosed in the docket.

Is mesalamine subject to biosimilar competition?

No. Mesalamine is a small-molecule active ingredient. Competition proceeds through the ANDA generic pathway rather than the biosimilar pathway.

References

1. U.S. District Court for the District of Delaware. (2015-2017). Shire Development LLC v. Apotex, Inc., No. 1:15-cv-01045, docket filings and termination record.

2. U.S. Food and Drug Administration. (2023). Lialda (mesalamine) delayed-release tablets: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

5. Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.